Mutant ADA2 in Vasculopathies
Key result
CRT-D reduces risk similarly across ischemic and nonischemic cardiomyopathy.
Structured PICO
P
Population
Patients with ischemic cardiomyopathy with NYHA class I or class II and patients with nonischemic cardiomyopathy
I
Intervention
CRT-D
CRT-D appears to have a similar effect size in patients with ischemic cardiomyopathy (NYHA class I or II) and nonischemic cardiomyopathy, though more prospective data are needed.
Limitations
- Sample-size limitations
- More prospective data are necessary to corroborate the beneficial effects of CRT-D among patients with asymptomatic ischemic cardiomyopathy
- sample-size limitations
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Supports CRT-D benefit across cardiomyopathy etiologies; leaves open prospective randomized confirmation.
Cite This Study
Kastner et al. (2014) conducted a letter in Ischemic cardiomyopathy with NYHA class I or II and nonischemic cardiomyopathy. CRT-D was evaluated. CRT-D demonstrated similar effect sizes (hazard ratios of 0.66, 0.65, and 0.57) across patients with ischemic cardiomyopathy (NYHA class I or II) and nonischemic cardiomyopathy.